Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $6.0 million.

  • Cumberland Pharmaceuticals' Other Non-Current Liabilities fell 228.77% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 228.77%. This contributed to the annual value of $6.3 million for FY2024, which is 238.27% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $6.0 million for Q3 2025, which was down 228.77% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $11.3 million in Q1 2022 and a low of $6.0 million during Q3 2025
  • Over the past 5 years, Cumberland Pharmaceuticals' median Other Non-Current Liabilities value was $7.0 million (recorded in 2023), while the average stood at $7.4 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 4455.66% in 2022, and later crashed by 3737.59% in 2023.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Other Non-Current Liabilities stood at $7.5 million in 2021, then increased by 1.28% to $7.6 million in 2022, then fell by 14.92% to $6.5 million in 2023, then fell by 2.38% to $6.3 million in 2024, then fell by 5.53% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $6.3 million for Q2 2025, and $6.0 million during Q1 2025.